TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiabetes Mellitus, Type 2

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Eligible age

65+ yrs

Accepts

Women

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing

Sponsor: Emory University

You may qualify if…

  • ✓ Postmenopausal women aged 65 years or older
  • ✓ Has type 2 diabetes
  • ✓ Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
  • ✓ Hemoglobin A1c \>7% within 3 months of the first visit.
  • ✓ Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
  • ✓ No osteoporosis confirmed on DEXA scan within 12 months
  • ✓ Able to provide informed consent and participate in all study assessments

You may not qualify if…

  • ✕ Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
  • ✕ eGFR \<30 ml/min in the last 3 months
  • ✕ Patients with a history of treatment with anti-osteoporosis agents
  • ✕ Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
  • ✕ Documented presence of prosthesis or devices in the spine or hip
  • ✕ Previous fragility fracture
  • ✕ Males
  • ✕ Moderate to severe gastroesophageal reflux disease based on patient history.

Where it's recruiting

Georgia

Atlanta

Source: ClinicalTrials.gov · NCT07428746 · last updated 2026-08-03